Dow Jones

38,686.32

1.51%

Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

Regístrate

STRO

Sutro Biopharma (STRO)

Sutro Biopharma Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:STRO

1 2 3 4 5 6 7 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
17/05/2024	16:00	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:STRO	Sutro Biopharma Inc
13/05/2024	15:34	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:STRO	Sutro Biopharma Inc
13/05/2024	15:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:STRO	Sutro Biopharma Inc
13/05/2024	15:30	GlobeNewswire Inc.	Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones	NASDAQ:STRO	Sutro Biopharma Inc
30/04/2024	07:00	GlobeNewswire Inc.	Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial	NASDAQ:STRO	Sutro Biopharma Inc
02/04/2024	05:18	GlobeNewswire Inc.	Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering	NASDAQ:STRO	Sutro Biopharma Inc
25/03/2024	15:30	GlobeNewswire Inc.	Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones	NASDAQ:STRO	Sutro Biopharma Inc
07/03/2024	15:32	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:STRO	Sutro Biopharma Inc
27/02/2024	15:33	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:STRO	Sutro Biopharma Inc
13/02/2024	11:16	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:STRO	Sutro Biopharma Inc
09/02/2024	15:25	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:STRO	Sutro Biopharma Inc
06/02/2024	15:05	GlobeNewswire Inc.	Sutro Biopharma to Participate in Upcoming Investor Conferences	NASDAQ:STRO	Sutro Biopharma Inc
29/01/2024	16:14	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:STRO	Sutro Biopharma Inc
04/01/2024	15:05	GlobeNewswire Inc.	Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC	NASDAQ:STRO	Sutro Biopharma Inc
14/12/2023	15:05	GlobeNewswire Inc.	Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024	NASDAQ:STRO	Sutro Biopharma Inc
11/12/2023	15:05	GlobeNewswire Inc.	Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023	NASDAQ:STRO	Sutro Biopharma Inc
04/12/2023	15:05	GlobeNewswire Inc.	Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit	NASDAQ:STRO	Sutro Biopharma Inc
27/11/2023	15:00	GlobeNewswire Inc.	Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates	NASDAQ:STRO	Sutro Biopharma Inc
21/11/2023	23:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:STRO	Sutro Biopharma Inc
21/11/2023	15:05	GlobeNewswire Inc.	Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer	NASDAQ:STRO	Sutro Biopharma Inc
13/11/2023	16:18	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:STRO	Sutro Biopharma Inc
13/11/2023	15:30	GlobeNewswire Inc.	Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones	NASDAQ:STRO	Sutro Biopharma Inc
22/10/2023	03:25	GlobeNewswire Inc.	Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023	NASDAQ:STRO	Sutro Biopharma Inc
16/10/2023	15:05	GlobeNewswire Inc.	Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference	NASDAQ:STRO	Sutro Biopharma Inc
19/09/2023	15:15	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:STRO	Sutro Biopharma Inc
19/09/2023	07:00	GlobeNewswire Inc.	Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer	NASDAQ:STRO	Sutro Biopharma Inc
10/08/2023	15:30	GlobeNewswire Inc.	Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones	NASDAQ:STRO	Sutro Biopharma Inc
29/06/2023	17:29	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:STRO	Sutro Biopharma Inc
26/06/2023	07:02	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:STRO	Sutro Biopharma Inc
26/06/2023	07:00	GlobeNewswire Inc.	Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration	NASDAQ:STRO	Sutro Biopharma Inc